Cargando…

Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice

Cow’s milk allergy is a common food allergy among infants. Improved hygiene conditions and loss of microbial diversity are associated with increased risk of allergy development. The intestinal immune system is essential for oral tolerance induction. In this respect, bacterial CpG DNA is known to dri...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mengshan, Thijssen, Suzan, Hennink, Wim E., Garssen, Johan, van Nostrum, Cornelus F., Willemsen, Linette E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872660/
https://www.ncbi.nlm.nih.gov/pubmed/36703973
http://dx.doi.org/10.3389/fimmu.2022.1053107
_version_ 1784877450411376640
author Liu, Mengshan
Thijssen, Suzan
Hennink, Wim E.
Garssen, Johan
van Nostrum, Cornelus F.
Willemsen, Linette E. M.
author_facet Liu, Mengshan
Thijssen, Suzan
Hennink, Wim E.
Garssen, Johan
van Nostrum, Cornelus F.
Willemsen, Linette E. M.
author_sort Liu, Mengshan
collection PubMed
description Cow’s milk allergy is a common food allergy among infants. Improved hygiene conditions and loss of microbial diversity are associated with increased risk of allergy development. The intestinal immune system is essential for oral tolerance induction. In this respect, bacterial CpG DNA is known to drive Th1 and regulatory T-cell (Treg) development via Toll-Like-Receptor 9 (TLR-9) signaling, skewing away from the allergic Th2 phenotype. We aimed to induce allergen specific tolerance via oral delivery of poly (lactic-co-glycolic acid) nanoparticles (NP) co-encapsulated with a selected β-lactoglobulin derived peptide (BLG-Pep) and TLR-9 ligand CpG oligodeoxynucleotide (CpG). In vivo, 3-4-week-old female C3H/HeOuJ mice housed in individually ventilated cages received 6-consecutive-daily gavages of either PBS, whey, BLG-Pep/NP, CpG/NP, a mixture of BLG-Pep/NP plus CpG/NP or co-encapsulated BLG-Pep+CpG/NP, before 5-weekly oral sensitizations with whey plus cholera toxin (CT) or only CT (sham) and were challenged with whey 5 days after the last sensitization. The co-encapsulated BLG-Pep+CpG/NP pretreatment, but not BLG-Pep/NP, CpG/NP or the mixture of BLG-Pep/NP plus CpG/NP, prevented the whey-induced allergic skin reactivity and prevented rise in serum BLG-specific IgE compared to whey-sensitized mice. Importantly, co-encapsulated BLG-Pep+CpG/NP pretreatment reduced dendritic cell (DC) activation and lowered the frequencies of PD-L1+ DC in the mesenteric lymph nodes compared to whey-sensitized mice. By contrast, co-encapsulated BLG-Pep+CpG/NP pretreatment increased the frequency of splenic PD-L1+ DC compared to the BLG-Pep/NP plus CpG/NP recipients, in association with lower Th2 development and increased Treg/Th2 and Th1/Th2 ratios in the spleen. Oral administration of PLGA NP co-encapsulated with BLG-Pep and CpG prevented rise in serum BLG-specific IgE and symptom development while lowering splenic Th2 cell frequency in these mice which were kept under strict hygienic conditions.
format Online
Article
Text
id pubmed-9872660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98726602023-01-25 Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice Liu, Mengshan Thijssen, Suzan Hennink, Wim E. Garssen, Johan van Nostrum, Cornelus F. Willemsen, Linette E. M. Front Immunol Immunology Cow’s milk allergy is a common food allergy among infants. Improved hygiene conditions and loss of microbial diversity are associated with increased risk of allergy development. The intestinal immune system is essential for oral tolerance induction. In this respect, bacterial CpG DNA is known to drive Th1 and regulatory T-cell (Treg) development via Toll-Like-Receptor 9 (TLR-9) signaling, skewing away from the allergic Th2 phenotype. We aimed to induce allergen specific tolerance via oral delivery of poly (lactic-co-glycolic acid) nanoparticles (NP) co-encapsulated with a selected β-lactoglobulin derived peptide (BLG-Pep) and TLR-9 ligand CpG oligodeoxynucleotide (CpG). In vivo, 3-4-week-old female C3H/HeOuJ mice housed in individually ventilated cages received 6-consecutive-daily gavages of either PBS, whey, BLG-Pep/NP, CpG/NP, a mixture of BLG-Pep/NP plus CpG/NP or co-encapsulated BLG-Pep+CpG/NP, before 5-weekly oral sensitizations with whey plus cholera toxin (CT) or only CT (sham) and were challenged with whey 5 days after the last sensitization. The co-encapsulated BLG-Pep+CpG/NP pretreatment, but not BLG-Pep/NP, CpG/NP or the mixture of BLG-Pep/NP plus CpG/NP, prevented the whey-induced allergic skin reactivity and prevented rise in serum BLG-specific IgE compared to whey-sensitized mice. Importantly, co-encapsulated BLG-Pep+CpG/NP pretreatment reduced dendritic cell (DC) activation and lowered the frequencies of PD-L1+ DC in the mesenteric lymph nodes compared to whey-sensitized mice. By contrast, co-encapsulated BLG-Pep+CpG/NP pretreatment increased the frequency of splenic PD-L1+ DC compared to the BLG-Pep/NP plus CpG/NP recipients, in association with lower Th2 development and increased Treg/Th2 and Th1/Th2 ratios in the spleen. Oral administration of PLGA NP co-encapsulated with BLG-Pep and CpG prevented rise in serum BLG-specific IgE and symptom development while lowering splenic Th2 cell frequency in these mice which were kept under strict hygienic conditions. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9872660/ /pubmed/36703973 http://dx.doi.org/10.3389/fimmu.2022.1053107 Text en Copyright © 2023 Liu, Thijssen, Hennink, Garssen, van Nostrum and Willemsen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Mengshan
Thijssen, Suzan
Hennink, Wim E.
Garssen, Johan
van Nostrum, Cornelus F.
Willemsen, Linette E. M.
Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title_full Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title_fullStr Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title_full_unstemmed Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title_short Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
title_sort oral pretreatment with β-lactoglobulin derived peptide and cpg co-encapsulated in plga nanoparticles prior to sensitizations attenuates cow’s milk allergy development in mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872660/
https://www.ncbi.nlm.nih.gov/pubmed/36703973
http://dx.doi.org/10.3389/fimmu.2022.1053107
work_keys_str_mv AT liumengshan oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice
AT thijssensuzan oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice
AT henninkwime oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice
AT garssenjohan oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice
AT vannostrumcornelusf oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice
AT willemsenlinetteem oralpretreatmentwithblactoglobulinderivedpeptideandcpgcoencapsulatedinplgananoparticlespriortosensitizationsattenuatescowsmilkallergydevelopmentinmice